Human Mutations That Confer Paclitaxel Resistance

Shanghua Yin, Rajat Bhattacharya, and Fernando Cabral

Abstract

The involvement of tubulin mutations as a cause of clinical drug resistance has been intensely debated in recent years. In the studies described here, we used transfection to test whether β1-tubulin mutations and polymorphisms found in cancer patients are able to confer resistance to drugs that target microtubules. Three of four mutations (A185T, A248V, R306C, but not G437S) that we tested caused paclitaxel resistance, as indicated by the following observations: (a) essentially 100% of cells selected in paclitaxel contained transfected mutant tubulin; (b) paclitaxel resistance could be turned off using tetracycline to turn off transgene expression; (c) paclitaxel resistance increased as mutant tubulin production increased. All the paclitaxel resistance mutations disrupted microtubule assembly, conferred increased sensitivity to microtubule-disruptive drugs, and produced defects in mitosis. The results are consistent with a mechanism in which tubulin mutations alter microtubule stability in a way that counteracts drug action. These studies show that human tumor cells can acquire spontaneous mutations in β1-tubulin that cause resistance to paclitaxel, and suggest that patients with some polymorphisms in β1-tubulin may require higher drug concentrations for effective therapy. Mol Cancer Ther; 9(2); OF1–9. ©2010 AACR.

Introduction

Microtubules are a major target in cancer chemotherapy. For example, the Vinca alkaloids have long been used in chemotherapeutic regimens for the treatment of leukemia, lymphoma, testicular carcinoma, and other malignancies. More recently, paclitaxel has emerged as a powerful drug for treating several solid tumors including breast, ovarian, and non–small cell lung carcinomas. In addition to these well-established drugs, several new agents that target microtubules are under development and many are already in clinical trials (1). Although microtubule-targeted drugs have proven to be highly effective for treating cancer, the development of drug resistance continues to present challenges to successful outcomes. Cell culture studies have identified several potential mechanisms by which resistance can develop, but to date, none of these has conclusively been shown to be a major cause of resistance in patients undergoing therapy (2, 3). One resistance mechanism that has received a lot of attention in recent years involves mutations in tubulin (4).

Microtubules assemble from heterodimers of α- and β-tubulin, but each of these proteins is encoded by at least six to seven genes that are expressed in a tissue-specific manner (5, 6). Although human α-tubulin proteins are highly homologous and differ by only a few amino acids, β-tubulins can differ by as many as 40 or more amino acid residues. The most variable region of β-tubulin involves the extreme COOH terminal fifteen residues, and these sequences have been used to classify β-tubulin proteins into the seven distinct isotypes: β1, β2, β3, β4a, β4b, β5, and β6 (7). Most tissues express varying amounts of at least three of these seven isotypes; thus, microtubule composition is heterogeneous and can differ considerably from one cell type to the next.

β1-Tubulin is the major isotype found in most mammalian tissues as well as most cultured tumor cell lines. Therefore, it is not surprising that most of the mutations that cause drug resistance in cell culture studies have been found in this isotype (8, 9). Given the high incidence of tubulin mutations as a cause of drug resistance in these studies, the question of whether tubulin mutations also play a major role in the development of in vivo resistance to drug treatment has been hotly debated in recent years. An initial report that tubulin mutations were common in patients with non–small cell lung carcinoma sparked a considerable amount of activity in this area (10). However, it was later found that the “mutations” came from sequencing pseudogenes that were amplified because of poor primer design (11), and several subsequent studies found little evidence for tubulin alterations in tumors from patients with a variety of malignancies (12–17). It should be noted, however, that although these latter studies found few tubulin mutations in tumor samples, most of those tumors came from patients who had not been treated with microtubule-targeted drugs and thus shed little light on whether tubulin mutations play a role in acquired resistance to drug therapy. Nevertheless, a
tubulin mutation and several polymorphisms were reported among these studies but their ability, if any, to confer drug resistance was not explored. To address this issue, we recreated the tubulin alterations as mutations in a β1-tubulin cDNA that is under the transcriptional control of a tetracycline-regulated promoter. We then transfected Chinese hamster ovary (CHO) cells with the cDNA to determine whether the mutations are capable of conferring drug resistance. The changes we tested included an R306C mutation found in 1 of 62 patients with breast cancer (14), A248V and A185T nonsynonymous single nucleotide polymorphisms found among 24 leukemia patients (18), and a G437S heterozygous polymorphism found in the tumor of a breast cancer patient who exhibited a partial response to an epothilone B analogue (19).

Materials and Methods

Site-Directed Mutagenesis and Transfection

CHO 1TA cells that produce a tetracycline-regulated transactivator (20) were used for all transfections. The cells were maintained in αMEM (Sigma-Aldrich) containing 5% fetal bovine serum (Gemini), 50 U/mL penicillin, 50 μg/mL streptomycin, 10 μg/mL puromycin, and 1 μg/mL tetracycline (all from Sigma-Aldrich). CHO β1-tubulin cDNA was cloned into the tetracycline-regulated mammalian expression vector, pTOFneo (20). The β1-tubulin cDNA also encoded a 9 amino acid hemagglutinin (HA) epitope tag (YPYDVPDYA) at the COOH-terminus for convenient detection of the protein. Site-directed mutagenesis was carried out with the QuickChange mutagenesis kit (Invitrogen) as recommended by the manufacturer. Stably transfected cells were selected in 2 μg/mL G418 plus 1 μg/mL tetracycline for 10 d.

Drug Resistance

G418-resistant transfected cells were seeded in duplicate into six-well dishes containing the drug (200 nmol/L paclitaxel or 50 nmol/L colcemid). One of the two drug-containing wells also contained 1 μg/mL tetracycline. A third well containing 50-fold fewer cells in αMEM plus 1 μg/mL tetracycline was used to estimate the number of viable cells that received. Cells were grown until visible colonies formed (7-10 d) and were stained with methylene blue as previously described (21). Finally, the plates were gently rinsed with water to remove excess stain and were then photographed.

Immunofluorescence

Cells were grown on sterile glass coverslips for 1 to 3 d, rinsed briefly in PBS, pre-extracted with microtubule buffer [20 mmol/L Tris-HCl (pH 6.8), 1 mmol/L MgCl2, 2 mmol/L EGTA, and 0.5% NP40] containing 4 μg/mL paclitaxel for 2 to 3 min on ice, and fixed in methanol at −20°C for at least 20 min. The fixed cells were then incubated with mouse monoclonal α-tubulin antibody DM1A (1:100; Sigma-Aldrich) and/or affinity-purified rabbit polyclonal anti-HA antibody (1:50, Bethyl Laboratories) for 30 to 60 min at 37°C in a humid chamber. After rinsing in PBS, the cells were incubated with 1:50 dilutions of Alexa 594-conjugated goat anti-mouse IgG (Molecular Probes) and/or Alexa 488-conjugated goat anti-rabbit IgG plus 1 μg/mL 4′,6-diamidino-2-phenylindole. The microtubules were visualized using an Optiphot microscope equipped with epifluorescence and a ×20 or ×60 objective (Nikon, Inc.). Images were captured using a Magnafire digital camera (Optronics).

Antibodies and Western blots

Cells grown in 24-well dishes until they were about 70% to 80% confluent were lysed in 1% SDS. Proteins were precipitated in five volumes of acetone, resuspended in 100 μL SDS sample buffer [0.0625 mol/L Tris-HCl (pH 6.8), 2.5% SDS, 5% 2-mercaptoethanol, 10% glycerol], separated on a 7.5% polyacrylamide SDS minigel, and transferred to PROTRAN nitrocellulose membranes (Schleicher and Schuell). After blocking the membranes with PBS containing 0.05% Tween 20 and 3% dry milk, they were incubated 45 to 60 min with a 1:2,000 dilution of β1-tubulin antibody Tub 2.1 (Sigma-Aldrich) and a 1:20,000 dilution of anti-actin antibody C4 (Chemicon International, Inc.). Immunoreactive bands were visualized by incubating the membrane 30 to 45 min in a 1:2,000 dilution of peroxidase-conjugated goat anti-mouse IgG (Sigma-Aldrich), washing in PBS, incubating with SuperSignal West Pico chemiluminescent substrate (Pierce), and exposing to X-ray film.

Extent of Cellular Tubulin Polymerization

The extent of tubulin polymerization, defined as the fraction of total cellular tubulin present in sedimentable microtubules, was measured as previously described (22). Cells were grown overnight in triplicate wells of 24-well dishes and were lysed in 100 μL of microtubule buffer containing 0.14 mol/L NaCl and 4 μg/mL paclitaxel. Lysates were scraped from the wells, transferred into 1.5 mL microcentrifuge tubes, and centrifuged at 12,000 × g for 15 min at 4°C. The supernatants carrying the unpolymerized tubulin were transferred to fresh tubes and the pellets containing the polymerized tubulin were solubilized in SDS sample buffer. Each sample (supernatant and pellet) also received 10 μL of a bacterial lysate expressing a glutathione S-transferase–tagged α-tubulin that acted as an internal control for potential losses of sample in subsequent steps. Proteins were precipitated using five volumes of acetone and were resuspended in 100 μL of SDS sample buffer. Equal volumes of samples were separated on 7.5% polyacrylamide SDS minigel (Bio-Rad) and transferred to nitrocellulose membranes. The membranes were incubated with antibody DM1A followed by Alexa 647-conjugated goat anti-mouse IgG (Invitrogen). Bands corresponding to α-tubulin and glutathione S-transferase–α-tubulin in each fraction were detected by fluorescence using a Storm Imager (Molecular Dynamics) and quantified using Image J. The extent of tubulin polymerization was calculated by first normalizing the α-tubulin in the pellet and supernatant fractions to the amount of glutathione S-transferase–α-tubulin present in those fractions. The normalized value...
from each pellet was then divided by the sum of the values from the pellet plus supernatant, and the resultant fraction was multiplied by 100%.

**Dose Response and IC\textsubscript{50}s**

Approximately 200 to 300 cells from each cell line were seeded into each of six replicate wells in 24-well dishes with increasing concentrations of drug and were incubated until visible colonies appeared (7-10 d). The surviving cells were then stained with 0.5% methylene blue in water, dried, and photographed. To calculate IC\textsubscript{50} values, the cell-associated dye was solubilized using 200 μL of 1% SDS in 50 mmol/L Tris-HCl (pH 6.8); 50 μL were transferred to a 96-well dish; and the absorbance was read at 630 nm using an Emax microplate reader (Molecular Dynamics). The absorbance at each drug concentration was normalized to the value with no drug present, and a graph of the normalized absorbance versus drug concentration was plotted for each sample using the ProFit software (QuantumSoft). Data points came from at least three experiments run in triplicate, and the IC\textsubscript{50} value was calculated from the graph as the concentration of drug that inhibited cell growth by 50%.

**Results**

**Mutations in β\textsubscript{1}-Tubulin Enable Cells to Form Colonies in Paclitaxel**

To test whether β-tubulin mutations or polymorphisms that have been identified in human tumors and normal tissues are able to confer resistance to antimitotic drugs, four mutations (A185T, A248V, R306C, and G437S) were introduced into HA\textsubscript{β1}-tubulin cDNA and transfected into CHO tTA cells that express a tetracycline regulated transactivator (20). Immunofluorescence with a HA tag antibody was used to monitor the transfection efficiency, and 4′,6-diamidino-2-phenylindole was used to stain nuclei. Transfected cells were enriched by selection with G418; tetracycline was also added to inhibit transgene expression and thereby limit any potential toxicity due to mutant HA\textsubscript{β1}-tubulin production. Equal numbers of G418-resistant cells were then seeded into two replicate wells of a six-well dish, both of which contained 200 nmol/L paclitaxel, but only one of which contained tetracycline to inhibit HA\textsubscript{β1}-tubulin production. A third well containing 50-fold fewer cells in medium with tetracycline but no paclitaxel was used to estimate the number of cells plated. As shown in Fig. 1, cells transfected with wild-type (WT) or mutant HA\textsubscript{β1}-tubulin were incubated in 200 nmol/L paclitaxel (Ptx; two wells on the left), with or without tetracycline (Tet), and grown until visible colonies appeared. Controls containing 50 times fewer cells and incubated in tetracycline alone are shown in the rightmost wells to estimate the relative number of cells seeded. Colonies were stained with methylene blue and were photographed.

Known to disrupt rather than promote microtubule assembly, but found no survivors in the drug (data not shown).

**Paclitaxel Selects for Cells That Express Mutant Tubulin**

Our prior experience indicated that only ~50% of cells selected in G418 are positive for expression of the transfected gene (23–25). This number is <100% because a break occurs in the circular plasmid during its integration into the genomic DNA and it can sometimes disrupt promoter or coding sequences necessary for the expression of the transfected gene. Additionally, the plasmid may occasionally integrate into areas of the genome with low transcriptional activity. On the other hand, we reasoned that if production of the mutant tubulin is required for paclitaxel resistance, then only the cells that express the mutant cDNA should be able to survive selection in paclitaxel. To test this prediction, G418-resistant populations of cells

![Figure 1. Survival of transfected cells in paclitaxel. Cells stably expressing wild-type (WT) or mutant HA\textsubscript{β1}-tubulin were incubated in 200 nmol/L paclitaxel (Ptx; two wells on the left), with or without tetracycline (Tet), and grown until visible colonies appeared. Controls containing 50 times fewer cells and incubated in tetracycline alone are shown in the rightmost wells to estimate the relative number of cells seeded. Colonies were stained with methylene blue and were photographed.](image-url)
transfected with each of the four mutant HAB1-tubulins were compared with the same populations that were subjected to further selection in a normally lethal dose of paclitaxel. As predicted, immunofluorescence analysis using an antibody to the HA tag showed that survivors of the G418 selection were a mixture of HAB1-tubulin–producing and HAB1-tubulin–nonproducing cells, whereas paclitaxel-resistant cells were uniformly positive for mutant HAB1-tubulin expression (Supplementary Fig. S1). These results provide further evidence that the production of HAB1-tubulin containing A185T, A248V, and R306C substitutions is sufficient to confer resistance to paclitaxel. Cells expressing the G437S mutation, however, were again unable to survive in the drug.

**Mutant Tubulin Production Correlates with the Degree of Paclitaxel Resistance**

To determine how much mutant HAB1-tubulin production is necessary to confer resistance, G418-resistant cells were reselected in 200 or 300 nmol/L paclitaxel and were then analyzed by Western blots using an antibody that recognizes both endogenous and transfected β-tubulin. For all three mutations that confer drug resistance, cells that survived selection in paclitaxel had a higher ratio of mutant to endogenous β-tubulin than the starting G418-resistant population (Fig. 2). Moreover, this ratio was significantly higher for the cells selected in 300 versus 200 nmol/L paclitaxel. It thus seems that the degree of paclitaxel resistance conferred by each of the mutations is proportional to the amount of mutant tubulin that is produced and incorporated into cellular microtubules. The data in Fig. 2 also suggest that of the three mutations that confer resistance to paclitaxel, A185T is able to do so at lower levels of expression than the other two.

**Mutant Tubulin Affects Microtubule Organization and Cell Division**

To assess whether the production of mutant tubulins could affect microtubule organization, transfected paclitaxel-resistant cells were grown in the absence of paclitaxel for 3 days and were stained with an anti-HA antibody.

**Microtubule Content Is Reduced in Cells That Produce Mutant Tubulin**

A microtubule fractionation procedure (22) was used to quantify the changes in microtubule assembly in stable...
cell lines that produce mutant tubulin. The procedure involved lysing cells in a microtubule-stabilizing buffer, separating microtubule polymer from soluble tubulin by centrifugation, and quantifying the amount of tubulin in the supernatant and pellet fractions. As shown in Fig. 4, ∼40% of the total tubulin in cells transfected with wild-type H\(\beta\)1-tubulin was found in the pellet (microtubule) fraction. This estimate agrees well with previously published data (20, 22, 23, 25–29). Cells transfected with the same cDNA, but containing A185T, A248V, or R306C mutations on the other hand, had a lower percentage of assembled tubulin. Moreover, the decrease in assembled tubulin was greater for the cells that expressed more of the mutant tubulin and were more paclitaxel resistant. This indicates that increasing the incorporation of mutant tubulin lowers microtubule stability and increases cellular resistance to paclitaxel. In contrast to these results, cells transfected with H\(\beta\)1-tubulin containing the G437S mutation that did not confer paclitaxel resistance had a normal percentage of assembled tubulin.

**Mutant Tubulin Alters the Sensitivity of Cells to Antimitotic Drugs**

Tubulin contains at least three topologically distinct drug-binding sites: a taxane-binding site in the \(\beta\) subunit, a colchicine-binding site in the \(\beta\) subunit, and a Vinca alkaloid–binding site at the interface between successive heterodimers in microtubule protofilaments (30–32). To determine whether the mutations in \(\beta\)-tubulin affect sensitivity to drugs other than paclitaxel, we tested the ability of transfected cells to form colonies in varying doses of paclitaxel, epothilone A, colcemid, and vinblastine. The dose-response curves shown in Fig. 5 confirmed that cells transfected with H\(\beta\)1-tubulin containing A185T, A248V, or R306C mutations were more resistant to paclitaxel (Fig. 5A). Similar results were obtained with epothilone A, another microtubule-stabilizing drug that is known to share the paclitaxel-binding site (Fig. 5B). In contrast, all three cell lines were more sensitive to both colcemid (Fig. 5C) and vinblastine (Fig. 5D), microtubule-destabilizing drugs that bind to the colchicine and Vinca alkaloid sites, respectively. Cells transfected with H\(\beta\)1-tubulin containing the G437S mutation, on the other hand, had normal sensitivity to all four drugs. A summary of the IC\(_{50}\)s for all of the cell lines to each of these drugs is provided in Table 1.

**Discussion**

The four mutations examined in this study came from published sequence information reported for cancer patients undergoing treatment. These included an R306C mutation found in 1 of 62 patients with breast cancer (14), A248V and A185T polymorphisms each found in 3 of 24 patients with hematologic malignancies (18), and a G437S polymorphism found in 1 of 17 patients with breast cancer (19). An S201C polymorphism was also reported in one of these studies (18), but cysteine is already the normal, conserved amino acid at this position. No clear correlation between these mutations/polymorphisms and patient response was noted in any of the studies. Despite being located at distant sites from one another on \(\beta\)-tubulin, three of the four amino acid substitutions we tested produced a similar phenotype when introduced as mutations into wild-type CHO cells. All three reduced microtubule polymer levels, conferred resistance to drugs that stabilize microtubules, and conferred increased sensitivity to drugs that destabilize microtubules. Thus, they resemble a large number of mutations we and others have previously characterized in paclitaxel-resistant cells, and they likely confer resistance by a mechanism that involves changes in microtubule assembly and stability that counteract the actions of the drugs (2, 33). We also tested a C201S mutation, but found no evidence that it is able to confer drug resistance (data not shown; ref. 29).

As previously argued, changes in drug binding are unlikely to contribute to resistance because decreased drug binding is a recessive phenotype that is rarely encountered in diploid cells. Moreover, decreased drug binding cannot explain the hypersensitivity of mutant cells to microtubule-destabilizing agents that bind to different sites, nor can it account for the ability of paclitaxel and related compounds to rescue the growth of mutant cells that have defects in cell division (2). Similarly, changes in tubulin levels or isotype composition resulting from transfection are an unlikely cause of resistance. Wild-type CHO cells have a \(\beta\)-tubulin composition that consists of 70% \(\beta\)1, 25% \(\beta\)4b, and 5% \(\beta\)5 (34,
35). All three endogenous isotypes, as well as all transfected isotypes we have tested, coassemble into all microtubules, but only overexpression of \( \beta_3 \) or \( \beta_5 \) is able to confer resistance to paclitaxel (29, 36). Although transfection of wild-type HA\( \beta_1 \)-tubulin cDNA does not confer drug resistance (Fig. 5; ref. 23), transfection of mutant HA\( \beta_1 \)-tubulin clearly does (Fig. 1). Therefore, it is unlikely that other changes resulting from transfection such as possible alterations in total tubulin levels or isotype ratios are responsible for resistance. As further evidence for this argument, we previously showed that overexpression of HA\( \beta_1 \)-tubulin produces only a small increase in cellular tubulin levels because excess \( \beta \)-tubulin (not in a heterodimer with \( \alpha \)-tubulin) is rapidly degraded.

**Figure 5.** Sensitivity of transfected cells to drugs that target microtubules. An equal number of cells (100-300) that stably express wild-type or mutant HA\( \beta_1 \)-tubulin cDNA were seeded into replicate wells in a 24-well dish with increasing concentrations of paclitaxel (A), epothilone A (B), colcemid (C), or vinblastine (D). The cells were grown until visible colonies appeared (7 d), and were then stained with methylene blue. To quantify the data, dye was extracted with SDS and the absorbance was read at 630 nm. The relative growth was calculated by dividing the absorbance at a given drug concentration by the absorbance in the absence of drug, and the quotient was plotted against the drug concentration. Points, mean of three independent experiments. The IC\(_{50}\)s and SDs are summarized in Table 1.

**Table 1.** Sensitivity of stably transfected cell lines to drugs that target microtubules

<table>
<thead>
<tr>
<th>Cell line</th>
<th>Paclitaxel</th>
<th>Epothilone A</th>
<th>Colcemid</th>
<th>Vinblastine</th>
</tr>
</thead>
<tbody>
<tr>
<td>Wild-type</td>
<td>50 ± 1.4 (1)</td>
<td>1.35 ± 0.02 (1)</td>
<td>31.7 ± 0.11 (1)</td>
<td>8.5 ± 0.16 (1)</td>
</tr>
<tr>
<td>A185T</td>
<td>366 ± 6 (7.3)</td>
<td>9.01 ± 0.14 (6.7)</td>
<td>18.9 ± 1.21 (−1.7)</td>
<td>1.7 ± 0.07 (−5)</td>
</tr>
<tr>
<td>A248V</td>
<td>282 ± 3 (5.6)</td>
<td>7.54 ± 0.35 (5.6)</td>
<td>7.2 ± 0.09 (−4.4)</td>
<td>1.3 ± 0.03 (−6.5)</td>
</tr>
<tr>
<td>R306C</td>
<td>321 ± 4 (6.4)</td>
<td>8.33 ± 0.28 (6.2)</td>
<td>13 ± 0.89 (−2.4)</td>
<td>1.7 ± 0.05 (−5)</td>
</tr>
<tr>
<td>G437S</td>
<td>49 ± 4 (1)</td>
<td>1.38 ± 0.04 (1)</td>
<td>31.1 ± 0.29 (1)</td>
<td>8.4 ± 0.05 (1)</td>
</tr>
</tbody>
</table>

NOTE: Values indicate nanomolar IC\(_{50}\) ± the SD. Numbers in parentheses are the fold-resistance (positive numbers) or fold-increased sensitivity (negative numbers) relative to the cell line transfected with wild-type HA\( \beta_1 \)-tubulin.
We conclude that mutant HAβ1-tubulin acts by incorporating into microtubules and altering their assembly and stability, a mechanism for which we have direct evidence (Fig. 4; ref. 22).

Consistent with the view that decreased microtubule stability is responsible for resistance to paclitaxel, all three mutations that cause resistance are located at sites that could influence subunit interactions. A structural model based on published atomic coordinates (31) indicates that alanine 248 is positioned in a loop that connects helix 7 to helix 8, and is near the intradimer interface where it could influence longitudinal subunit interactions along protofilaments (Fig. 6). Alanine 185 is a buried residue in helix 5 near the GTP-binding site in β-tubulin and could be influencing interdimer interactions along protofilaments. Arginine 306 is found in a highly conserved small helical region of a loop that connects helix 9 and sheet 8. It is a surface-exposed residue that is positioned in a region that could influence lateral interactions between protofilaments. The G437S mutation (not shown in Fig. 6) that fails to alter microtubule assembly or confer drug resistance, on the other hand, is located on the outer surface of assembled microtubules (38).

A review of the data from several laboratories clearly implicates mutations in tubulin as a major cause of resistance to paclitaxel and other antimitotic drugs in mammalian cell culture models (8). For example, in a single-step selection for resistance to paclitaxel, >90% of the isolated clones had properties consistent with mutations in tubulin, whereas the remainder had the multidrug resistance phenotype (39). For colchicine and vinblastine, on the other hand, the majority of resistant cell lines had the multidrug resistance phenotype and only ~15% were tubulin mutants (40). Given the high incidence of tubulin mutations in these and other selections, it was natural to assume that tubulin mutations might also be responsible for chemoresistance in patients.

One of the first studies to test this prediction examined 49 patients with non–small cell lung cancer. The authors reported that 16 of these patients had mutations in the β1-tubulin gene and exhibited no objective response to subsequent paclitaxel treatment. Of the remaining 33 patients with no mutations, 13 responded to therapy (10). These results have since been called into question, however, by studies demonstrating that the exon primers used in the earlier study were able to amplify pseudogenes in addition to the authentic β1-tubulin gene (11). Subsequent work using intron primers to avoid the amplification of pseudogenes have gone on to show that tubulin mutations are exceedingly rare in human tumors and led to the conclusion that β1-tubulin mutations are unlikely to be a significant cause of treatment failure in patients (12–17). It should be pointed out, however, that most of these later studies focused on patients who were not pretreated with paclitaxel or other taxanes. Thus, the studies indicate that β1-tubulin mutations are an unlikely cause of inherent drug resistance, but they do not address the possibility that such mutations might be responsible for acquired resistance during or following treatment. One study did look for tubulin mutations as a possible cause of acquired resistance, but again found no alterations in the β1-tubulin gene among 30 paclitaxel-resistant samples that included tumors from 9 patients with ovarian cancer, 9 cell lines selected for paclitaxel resistance in cell culture, and 12 ovarian tumor xenografts in nude mice (41). These negative results could have been caused in part by methodologic problems (discussed below), but the data from this study support the view that tubulin mutations are also not involved in acquired drug resistance.
In contrast to these reports, some recent observations support the idea that tubulin alterations could be playing a role in clinical resistance to microtubule-targeted drugs. In one particularly interesting study, human tumor xenografts from 10 children with acute lymphocytic leukemia were established in nude mice and assayed for vincristine sensitivity in cell culture (42). The results indicated that drug sensitivity of the cells in culture correlated with favorable patient outcomes. Moreover, the more resistant cells tended to have higher amounts of microtubule polymer. Comparison of the two xenografts having the highest and lowest amount of polymerized tubulin further showed that the cells with higher microtubule polymer were not only more resistant to vincristine, they were also more sensitive to paclitaxel compared with the cells with lower polymer levels. The relationship between drug resistance and microtubule polymer levels was further supported by the observation that polymer levels again increased in two sublines from one of the xenografts that acquired additional drug resistance by treating the animals with vincristine. A second study has indicated that vinorelbine, a Vinca alkaloid that destabilizes microtubules, is particularly effective in patients with metastatic breast carcinoma who have failed anthracycline and taxane treatment (43). Although neither study provided sequence information for tubulin, the phenotypes of increased polymer levels and enhanced paclitaxel sensitivity in vincristine-resistant cells, as well as increased Vinca alkaloid sensitivity in paclitaxel-resistant patients agree with phenotypes reported for drug-resistant cells with mutations in tubulin reported here and elsewhere (see references 2, 3, 8 for reviews).

We are of the opinion that if tubulin mutations can cause drug resistance in a cell culture model, they should be capable of producing resistance in clinical settings. Why then has it proved to be so difficult to find evidence for tubulin mutations in human cancer? Several factors may have contributed to this conundrum. (a) As already mentioned, it is unreasonable to expect a high incidence of tubulin mutations as a cause of inherent drug resistance in untreated patients. Tubulin is a highly conserved and essential protein; most mutations will cause defects in mitosis leading to cell death. Thus, tubulin mutations will rarely be found in unselected tumor cell populations. They are more likely to be found in relapsed patients. (b) Tumor biopsies contain many noncancerous cells that may obscure the presence of a mutation in DNA sequencing experiments. (c) Most cells express multiple tubulin genes and it is well established that mutations in both α- and β-tubulin can cause drug resistance (39). Thus, potential drug resistance mutations may be missed when only the β1-tubulin gene is sequenced.

Despite limitations that may previously have caused underreporting of tubulin mutations in patients being treated for cancer, we believe that even with improved approaches, these mutations will continue to be difficult to find because other mechanisms of resistance may occur much more frequently. Recent studies, for example, have indicated that expression of β3-tubulin, an isoform that is normally restricted to neuronal tissue, correlates well with poor patient response to chemotherapy (44). It has been confirmed that overexpression of β3-tubulin can cause paclitaxel resistance in cell culture models (45), but it should be noted that high levels of expression are needed and that only a marginal degree of resistance is gained (36). Thus, although β3 expression may contribute to drug resistance, it is unlikely to be a major cause of resistance. The most likely cause of treatment failure may simply be patient-to-patient variability in pharmacologic parameters such as drug distribution, metabolism, and excretion that may limit the amount of drug that is actually delivered to the tumor cells (46). In support of this notion, it has been observed that some patients who fail treatment with paclitaxel remain sensitive to docetaxel, a drug with a similar mechanism of action that binds to the same site on the protein (47). In addition, it has been reported that formulations of paclitaxel that alter the pharmacologic properties of the drug seem to be more effective in treating tumors (48, 49). Continued improvements in drug design and protocols for the administration of paclitaxel and other taxanes may ultimately decrease or, perhaps even eliminate, pharmacologic barriers to drug action. As that happens, we predict that tubulin mutations, such as the ones described here, will emerge as a major cause of acquired drug resistance in patients who relapse after successful therapy with these drugs.

Tubulin polymorphisms, in contrast to tumor-specific mutations in tubulin, occur at an appreciable frequency in humans. One of the most common seems to be an L217I polymorphism reported by several groups (11, 14, 16, 41). Nonsynonymous changes occur less frequently but are still appreciable. For example, the A248V and A185T polymorphisms examined here were found in 12.5% of the patients in one study (18), whereas G437S was found in 5.9% of the patients in a second group (19). The fact that two of the three polymorphisms were shown to be capable of conferring resistance to paclitaxel suggests that these differences in sequence could contribute to variability in patient response to antimitotic drugs. Although the tumor cells in such patients might be relatively resistant compared with patients without these tubulin alterations, their bone marrow would likely also be relatively resistant, allowing higher doses of chemotherapy to be administered. Thus, the presence of the polymorphisms might not ultimately contribute to the success or failure of chemotherapy, but they might be useful guides to the doses of drug that should be administered for optimum patient response.

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

Grant Support

NIH Grant CA85935 (F. Cabral).

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received 7/22/09; revised 11/9/09; accepted 11/19/09; published OnlineFirst 1/26/10.
References

Molecular Cancer Therapeutics

Human Mutations That Confer Paclitaxel Resistance

Shanghua Yin, Rajat Bhattacharya and Fernando Cabral

Mol Cancer Ther  Published OnlineFirst January 26, 2010.

Updated version
Access the most recent version of this article at:
doi:10.1158/1535-7163.MCT-09-0674

Supplementary Material
Access the most recent supplemental material at:
http://mct.aacrjournals.org/content/suppl/2010/01/25/1535-7163.MCT-09-0674.DC1

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.